Enliven Therapeutics ELVN Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's short-term investments?
- Enliven Therapeutics (ELVN) reported short-term investments of $320.22M in Q1 2026.
- How has Enliven Therapeutics's short-term investments changed year-over-year?
- Enliven Therapeutics's short-term investments increased by 70.5% year-over-year, from $187.85M to $320.22M.
- What is the long-term trend for Enliven Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Enliven Therapeutics's short-term investments has grown at a 55.1% compound annual growth rate (CAGR), from $40.52M to $363.73M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.